WORCESTER, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, announced today that Timothy P. Coleman, President and Chief Executive Officer, will present a corporate overview and update at the Needham & Company’s 15th Annual Healthcare Conference on April 12-13, 2016 in New York City. The Nemucore presentation will take place at 09:20 AM on Wednesday, April 13, 2016.
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore’s most advanced candidate NMI-900, a potential “best-in-class” therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late-2016. Two additional candidates are anticipated to enter clinical trial development later in 2017, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at www.Nemucore.com.
Contacts: Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen L. Bergman (650) 575-1509 kbergman@bccpartners.com Jen LaVin (207) 360-0473 jlavin@bccpartners.com
